Table 1.

Comparison of Gravimetric and Echocardiographic Data in Doxorubicin Cardiomyopathy

Variable	WT Saline (n=10)	WT Dox (n=10)	ITCH‐Tg Saline (n=10)	ITCH‐Tg Dox (n=10)
BW before, g	23.6±1.5	23.2±1.4	23.6±2.1	23.9±1.5
BW after, g	23.7±1.6	19.4±2.5a	23.9±2.1b	20.9±1.9a, b, c
HW after, mg	115.6±11.8	76.5±9.4a	117.7±13.5b	95.7±12.4a, b, c
HW/BW ratio	4.88±0.45	3.97±0.33a	4.92±0.35b	4.56±0.40a, b, c
Heart rate, bpm	548±19	542±17	567±12	554±14
IVSd, mm	0.82±0.08	0.72±0.09a	0.84±0.06b	0.74±0.07a, c
LVEDD, mm	2.69±0.11	3.04±0.14a	2.72±0.08b	2.83±0.13a, b, c
LVPWd, mm	0.87±0.13	0.73±0.12a	0.90±0.13b	0.77±0.14a, c
%FS (%)	54±5	38±7a	55±4b	51±6a, b, c

Mean±SD. %FS indicates fractioning shortening; bpm, beats per minute; BW, body weight; Dox, doxorubicin; HW, heart weight; ITCH‐Tg, cardiac‐specific overexpression of ITCH transgenic mouse; IVSd, interventricular septal diameter; LVEDD, left ventricular end‐diastole dimension; LVPWd, left ventricular posterior wall diameter; WT, wild type.

^a P<0.05 vs WT saline group.

^b P<0.05 vs WT Dox group.

^c P<0.05 vs ITCH‐Tg saline group by ANOVA with Scheffe post hoc test.